mTOR activation as a mechanism for sex differences in vaccine-induced immunity

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1F32AI186453-01

Grant search

Key facts

  • Disease

    Unspecified
  • Start & end year

    2024
    2025
  • Known Financial Commitments (USD)

    $74,764
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    POSTDOCTORAL FELLOW Laura St Clair
  • Research Location

    United States of America
  • Lead Research Institution

    JOHNS HOPKINS UNIVERSITY
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project Summary Biological sex has profound effects on the effectiveness of vaccines that protect against pathogens of pandemic potential, including influenza A viruses. Following influenza vaccination, females of reproductive ages (18-49 years) produce greater antiviral antibody responses than age-matched males, which correlates with greater estradiol (E2) concentrations in females. How estrogens drive greater B cell activation and antibody production after vaccination is not known. Estrogen receptor signaling in B cells might alter metabolic signaling to cause sex differences in vaccine-induced immunity. Activation of mTOR, in particular, and a switch towards β-oxidation as a primary energy source has been identified as indispensable for B cell proliferation, differentiation, and antibody production. Prior studies have demonstrated that females show greater preference for the use β- oxidation for energy production when under high energy demand. Thus, I hypothesized that differential activation of mTOR and downstream utilization of lipids for β-oxidation may be a potential mediator of sex differences in vaccine-induced immunity. My preliminary data show that after H1N1 vaccination in mice, adult females have greater activation of mTOR and mTOR-related proteins in splenic B cells than age-matched males. I hypothesize that greater mTOR activation in B cells from females is partially regulated by E2 through an ERα-mTOR feedback loop. My central hypothesis is that sex steroid signaling causes distinct metabolic signatures in B cells and that differential regulation of mTOR is the central mechanism governing sex-specific differences in vaccine-mediated humoral immunity. In Aim 1, I will test whether manipulation of mTOR and selected downstream proteins using small molecule agonist and antagonist can reverse sex differences in immune responses using a mouse model of influenza vaccination. I will use immunofluorescence assays and seahorse analysis of mitochondrial respiration to dissect sex differences in metabolic activation in B cells following vaccination, which will be correlated with measures of protective immunity. In Aim 2, I will examine the effects of sex chromosome complement and sex steroid signaling on both mTOR activation and metabolic activation of B cells. Through these experiments, I seek to define the cellular mechanisms mediating sex differences in vaccine-induced immunity. These results have significant translational application. As a fellow, the research that I have outlined is crucial to extend my training in animal models, viral immunology, sex-based biology, and biomedical research to refine my expertise in using metabolomics-based approaches to gain mechanistic insight into biological phenomena.